相似文献
1
Renin-angiotensin system blockers and COVID-19.
BMC Med. 2021 Jun 4;19(1):136. doi: 10.1186/s12916-021-02012-6.
2
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Ann Intern Med. 2021 Jan;174(1):W17. doi: 10.7326/L20-1355. Epub 2020 Dec 1.
3
Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Korean J Intern Med. 2021 Mar;36(Suppl 1):S123-S131. doi: 10.3904/kjim.2020.390. Epub 2021 Feb 10.
4
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
5
The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks.
Hypertens Res. 2024 Sep;47(9):2598-2600. doi: 10.1038/s41440-024-01772-x. Epub 2024 Jul 1.
6
COVID-19 and inhibitors of the renin-angiotensin-aldosterone system.
Expert Rev Anti Infect Ther. 2021 Jul;19(7):815-816. doi: 10.1080/14787210.2021.1851197. Epub 2020 Nov 26.
7
COVID-19 and the Renin-Angiotensin-Aldosterone System.
Clin Infect Dis. 2021 Mar 15;72(6):1105-1107. doi: 10.1093/cid/ciaa818.
8
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.
J Med Virol. 2021 Apr;93(4):1873-1874. doi: 10.1002/jmv.26672. Epub 2020 Nov 22.
9
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
10
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Ann Intern Med. 2020 Dec 15;173(12):167-168. doi: 10.7326/L20-1293. Epub 2020 Oct 27.
引用本文的文献
1
The Renin-Angiotensin System (RAS) in COVID-19 Disease: Where We Are 3 Years after the Beginning of the Pandemic.
Microorganisms. 2024 Mar 14;12(3):583. doi: 10.3390/microorganisms12030583.
2
Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction.
Front Cardiovasc Med. 2022 Jun 17;9:910100. doi: 10.3389/fcvm.2022.910100. eCollection 2022.
3
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.
Biomed Pharmacother. 2022 Jan;145:112420. doi: 10.1016/j.biopha.2021.112420. Epub 2021 Nov 12.
本文引用的文献
1
Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
BMC Med. 2021 May 12;19(1):118. doi: 10.1186/s12916-021-01992-9.
2
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials.
Front Pharmacol. 2021 Mar 29;12:603736. doi: 10.3389/fphar.2021.603736. eCollection 2021.
3
Renin-angiotensin system blockade in the COVID-19 pandemic.
Clin Kidney J. 2021 Feb 2;14(Suppl 1):i48-i59. doi: 10.1093/ckj/sfab026. eCollection 2021 Mar.
4
Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.
Front Physiol. 2021 Feb 22;12:624052. doi: 10.3389/fphys.2021.624052. eCollection 2021.
5
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
JAMA. 2021 Jan 19;325(3):254-264. doi: 10.1001/jama.2020.25864.
6
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Lancet Respir Med. 2021 Mar;9(3):275-284. doi: 10.1016/S2213-2600(20)30558-0. Epub 2021 Jan 7.
7
Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.
J Hypertens. 2021 Apr 1;39(4):795-805. doi: 10.1097/HJH.0000000000002706.
8
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
J Hypertens. 2021 Feb 1;39(2):367-375. doi: 10.1097/HJH.0000000000002658.
9
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.
Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15.
10
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
Zotero 插件